Copyright
©The Author(s) 2016.
World J Gastrointest Endosc. Jan 10, 2016; 8(1): 4-12
Published online Jan 10, 2016. doi: 10.4253/wjge.v8.i1.4
Published online Jan 10, 2016. doi: 10.4253/wjge.v8.i1.4
Prep | % Adequate | Lesion detection rate | Cost1 | |
4 L PEG | Single | 51%-88%[16,64] | PDR 50.5%-51%[26,51] | PEG 3350 with electrolytes 4 L |
Split | 71.3%-92.1%[23,51] | ADR 27.8-34.3%[51,70] | $26.59 | |
2 L PEG | Single | 83.5%-91%[45,64] | ADR 18.8%[70] | Moviprep 100 g/1 kit |
Split | 74.4%-93.5%[45,48] | $91.55 | ||
MiraLAX | Single | 67.8%-81.8%[29,31] | PDR 47%[26] | MiraLAX 8.3oz/238 g |
Split | $13.99 | |||
Sodium Phosphate | 84.3%-90%[35,37] | Not Available | OsmoPrep 32 tabs | |
$163.05 | ||||
Sodium Picosulfate | Single | 61.5%-82.6%[49,51] | PDR 38.5%-42.9%[51,53] | Prepopik, 2 pkts |
Split | 81.6%-87.9%[49,50] | ADR 23.8%-31.3%[51,53] | $121.31 | |
Oral Sulfate Solution | SuPrep | 94.7%-98.4%[44,53] | PDR 50.9%[53] | SuPrep 1 kit |
$49.09 | ||||
Suclear | 93.5%[45] | ADR 26%[53] | Suclear | |
$76.38 |
Prep | Advantages | Disadvantages |
4 L PEG | Effective | Poor taste |
Safe in most populations | Very high volumes | |
Poorly tolerated by patients | ||
2 L PEG | Effective | Poor taste |
Safe in most populations | High volumes | |
High cost | ||
MiraLAX | Well tolerated by patients | Not as effective as prescription PEG preparations |
Available over the counter | Rare reports of hyponatremia | |
Existing studies indicate it is safe | ||
Sodium phosphate | Available as oral tab | Inappropriate for use in patients with renal disease, volume depletion, heart or liver failure, or who are taking ACEi or NSAIDs |
Well tolerated by patients | Risk of acute phosphate nephropathy and subsequent chronic kidney disease | |
Sodium picosulfate | Cost | |
Well tolerated by patients | Not as effective as PEG or OSS | |
OSS | Small volumes to be ingested | Inappropriate for patients with heart failure, renal insufficiency, end stage liver disease, or baseline electrolyte abnormalities |
Pleasant taste | High cost | |
Well tolerated by patients | High cost | |
Highly effective | Not as well studied | |
Available as oral tab |
- Citation: Harrison NM, Hjelkrem MC. Bowel cleansing before colonoscopy: Balancing efficacy, safety, cost and patient tolerance. World J Gastrointest Endosc 2016; 8(1): 4-12
- URL: https://www.wjgnet.com/1948-5190/full/v8/i1/4.htm
- DOI: https://dx.doi.org/10.4253/wjge.v8.i1.4